Alnylam Pharmace. buy Truist Financial Co.
Start price
08.01.26
/
50%
€343.00
Target price
08.01.27
€454.00
Performance (%)
0.29%
Price
12:22
€344.00
Summary
This prediction is currently active. The BUY prediction by Truist_Financial_Co_ for Alnylam Pharmace. is nearly unchanged. This prediction currently runs until 08.01.27. The prediction end date can be changed by Truist_Financial_Co_ at any time. Truist_Financial_Co_ has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w |
|---|---|
| Alnylam Pharmace. | 0.29% |
| iShares Core DAX® | 2.659% |
| iShares Nasdaq 100 | 0.916% |
| iShares Nikkei 225® | 2.426% |
| iShares S&P 500 | 1.230% |
Comments by Truist_Financial_Co_ for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Truist Financial Corporation from $535.00 to $530.00. They now have a "buy" rating on the stock.
Ratings data for ALNY provided by MarketBeat
Stopped prediction by Truist_Financial_Co_ for Alnylam Pharmace.
Alnylam Pharmace.
Start price
Target price
Perf. (%)
€418.20
17.10.25
17.10.25
€457.16
17.10.26
17.10.26
-17.74%
12:22
12:22
